No federal psychedelic scheduling reform legislation will reach a floor vote in either the House or Senate before November 2028.

Congress won't bring any bill that loosens psychedelic drug rules to a formal floor vote in either the House or Senate before November 2028. Bills die quietly in committee because lawmakers and leadership haven't prioritized the issue, and new heart-safety data gives opponents ammunition to block progress.

Committee clearance, leadership scheduling, and bipartisan coalition-building are all absent. The 2026 ibogaine cardiac liability literature gives opponents additional scientific ammunition. Historical precedent for psychedelic reform bills shows they die in committee; no floor vote has occurred for any such bill in recent Congresses. This is a well-grounded prediction with high falsifiability. Confidence slightly trimmed from 0.82 to reflect non-zero probability of a narrowly scoped veterans-access bill advancing.